Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Home > Science Hub > Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer
Back to the list

April 12, 2022

Dirix L et al. Breast Cancer Research and Treatments, 2022

Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer

Download Publication

You might also be interested by

CellTalk Blog

Optimizing T-Cell Engager (TCE) Development: Insights You Need for Clinical and Regulatory Success

May 27, 2025

More info

Brochures & Infographics

Regulations for Global Trials Assay

May 16, 2025

More info

Brochures & Infographics

Solutions for T cell engager (TCE) programs

May 16, 2025

More info

Posters

Comparable detection of large tumor-derived vesicles (oncosomes) by known CTC platforms: potential new analyte for biomarker monitoring?

April 27, 2025

More info